Unmasking China?s Corruption Endemic : A Healthcare Sector in Crisis

Apart from the well-know anti-corruption campaign within the Chinese Communist Party (CCP), another significant crusade against corruption is in the works. China?s lacking healthcare sector is currently under severe scrutiny for widespread corruption that have come to light since the COVID-19 pandemic settled two years ago.

Investigators have charged over 200 plus hospital heads, with the CCP specifically targeting the medical sector which has received public funding worth billions of US dollars during the pandemic.

China?s sweeping anti-corruption campaign in the healthcare sector, while long overdue, has exposed a systemic issue that has left both citizens and companies charting an environment fraught with distrust and uncertainty. The crackdown has so far targeted everything, from bribes and kickbacks to inflated procurement costs in public hospitals.

While such actions have largely aimed to clean up a sector riddled with unethical practices, it has also brought to light the severity of how deeply corruption has permeated the healthcare system, heightening public anxiety and undermining trust in one of the most critical aspects of governance ? access to affordable and reliable healthcare.

The healthcare sector in China, built around sprawling public hospitals and their networks has struggled under the dual pressures of providing affordable care for an ageing population while managing constrained budgets. This imbalance has created fertile ground for corrupt practices.

Hospital managers, tasked with balancing the books, have often resorted to dubious practices such as overprescribing treatments or accepting bribes for expensive equipment purchases.

A National Health Commission study revealed that between 2013 and 2022, 70% of corruption cases in healthcare were tied to equipment procurement and pharmaceuticals, pointing to a sector where systemic vulnerabilities are exploited at an alarming scale.

The cases of two senior pharmaceutical company executives ? Winning Health Technology Group chairman Zhou Wei and Fan Zhihe, chairman of Shanghai Serum Bio-Technology, for instance, who have been under investigation for alleged corruption, has also raised attention to the fact that such cases are only going to rise given the investigation of high-profile entities.

These forms of sector-specific investigations have also been on a rise since Xi Jinping took over the leadership position in the CCP. More so, the investigations into the health sector importantly came under scanner right after China diluted its stringent zero-covid policy, suggesting that the period of curfew in the country was also used to enhance corrupt practices in the name of safeguarding health of all.

On the other hand, for ordinary citizens, corruption has transformed healthcare into a source of anxiety. The pervasive belief that ?seeing a doctor is difficult and expensive? has reflected not only on the challenges of affordability but also a growing cynicism about the system?s integrity.

The current campaign, which seems to be targeting not just individuals but also institutional networks, has further highlighted the complexity of the problem. High-profile investigations, such as those at Beijing?s prestigious Fuwai Hospital, also showcased that even elite institutions are not immune from the menace of corruption in China.

For foreign pharmaceutical and med-tech companies, particularly European firms, the anti-corruption drive is a double-edged sword. On one hand, a cleaner procurement system could lower operationally costs. On the other, Beijing?s tendency to blame corporate greed for systemic issues, paired with its preference for state-led solutions, signals a challenging business environment.

Xi Jinping?s Corruption Crusade: A Clean-up act or Source of Centralising Power?

China?s approach mirrors broader trends under Xi Jinping?s governance, emphasizing state intervention to guarantee access to basic services under the banner of ?common prosperity.? While this aligns with public sentiment against corporate greed, it raises concerns about the long-term consequences of limiting market-driven solutions.

Price controls, a cornerstone of recent reforms like volume-based procurement (VBP), may reduce immediate costs but risk stifling innovation. Historical precedents, such as Japan?s pharmaceutical decline following similar policies, suggest that overreach in controlling prices could undermine R&D investment, threatening the very sustainability of healthcare advancements.

Furthermore, with Xi Jinping?s anti-corruption campaign there has been some respite with many hoping for greater due diligence to prosecute the guilty. However, much of these investigations have focused on eliminating political dissenters.

The program has so far prosecuted very high-level state-level officials, deputy state-level officers, military commission members, dozens of ministerial-level officers, and hundreds of deputy ministerial-level officers.

According to a report by the Indo-Pacific Centre for Strategic Communications (IPCSC), 111,000 people have been fined including provincial and provincial-level cadres, 633 department-level cadres, 669 district-level cadres, and 1,000 townships.

The fact that most political affiliates have known that some pharmaceutical companies bribe hospital bosses and party secretaries for sales has also caused some panic within the party for not having reported such instances.

The irregularities in such cases have more importantly been traced back too many top officials who share their cuts in order to maintain discretion about kickbacks on such deals.

The role of inadequate oversight also cannot be dismissed when such cases come to light. Despite numerous cases being exposed in the public domain, the number of businesses and party officials prosecuted has not decreased.

On the contrary, it appears to have evolved into a political tussle among various factions in China. With Xi Jinping?s anti-corruption programs in full force, few in the country believe that these cases will lead to meaningful change in the behaviour of party officials. Instead, many perceive these prosecutions as politically motivated, with little intention of genuinely holding the guilty accountable.

(MeKongNews)